Metastatic Uveal Melanoma Clinical Trial
Official title:
A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to see if the combination of entinostat and pembrolizumab can be an effective treatment for patients with melanoma of the eye (uveal melanoma) that has spread to other sites of the body (metastatic disease). Pembrolizumab is an antibody that helps the immune system to attack cancer cells. Although pembrolizumab has proven clinical efficacy in treating patients with metastatic cutaneous melanoma, an effect on metastatic uveal melanoma has not been established. Entinostat is a histone deacetylase (HDAC) inhibitor that has effects on both cancer cells and immune regulatory cells, thus potentially enhancing the effects of immunotherapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03068624 -
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
Recruiting |
NCT04728633 -
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05987332 -
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
|
Phase 2/Phase 3 | |
Completed |
NCT01551459 -
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
Completed |
NCT01585194 -
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Withdrawn |
NCT01328106 -
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04552223 -
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT05607095 -
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT01587352 -
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
Active, not recruiting |
NCT03472586 -
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
|
Phase 2 | |
Active, not recruiting |
NCT03025256 -
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
|
Phase 1 | |
Terminated |
NCT04879017 -
FHD-286 in Subjects With Metastatic Uveal Melanoma
|
Phase 1 | |
Terminated |
NCT01814046 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
|
Phase 2 | |
Recruiting |
NCT03947385 -
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03865212 -
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT05022901 -
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
|
Phase 3 | |
Recruiting |
NCT05282901 -
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
|
Phase 2 | |
Recruiting |
NCT05415072 -
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
|
Phase 1/Phase 2 |